Back to results
US 2026/0284151 A1Published application
Combination therapies of prednisone and uricase molecules and uses thereof
AssigneeHorizon Therapeutics USA, Inc.
InventorsJeffrey D. KENT, Brian LAMOREAUX
Life of this patent
Estimating the term…
Abstract
Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and/or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.
Claims15
1-81. (canceled)
A method of treating gout in a subject in need thereof, comprising repeatedly administering to the subject both pegloticase and methylprednisolone during a treatment period, wherein the methylprednisolone is administered as a pre-dose prophylaxis prior to each administration of pegloticase;
- wherein 4 to 12 mg of pegloticase and 40 to 120 mg of methylprednisolone are administered once every 14 days during the treatment period;
- and
- wherein no serum uric acid lowering therapeutic besides pegloticase is administered during the course of administering pegloticase.
Dependencies are inferred from the claim text.